These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1084 related items for PubMed ID: 15128354

  • 1. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ.
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [Abstract] [Full Text] [Related]

  • 2. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [Abstract] [Full Text] [Related]

  • 3. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
    Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD.
    Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients.
    Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P.
    Dis Colon Rectum; 2007 Mar; 50(3):331-6. PubMed ID: 17252288
    [Abstract] [Full Text] [Related]

  • 5. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
    Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Apr 01; 19(7):749-54. PubMed ID: 15043515
    [Abstract] [Full Text] [Related]

  • 6. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov 01; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 7. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.
    Aliment Pharmacol Ther; 2009 Aug 01; 30(3):253-64. PubMed ID: 19438424
    [Abstract] [Full Text] [Related]

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 01; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 10. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 11. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis.
    Markel TA, Lou DC, Pfefferkorn M, Scherer LR, West K, Rouse T, Engum S, Ladd A, Rescorla FJ, Billmire DF.
    Surgery; 2008 Oct 01; 144(4):540-5; discussion 545-7. PubMed ID: 18847637
    [Abstract] [Full Text] [Related]

  • 12. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club.
    Gastroenterology; 2010 Feb 01; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [Abstract] [Full Text] [Related]

  • 13. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease.
    El-Hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-Ussing O, Olaison G.
    Scand J Gastroenterol; 2012 Jun 01; 47(6):662-8. PubMed ID: 22486168
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease.
    Myrelid P, Olaison G, Sjödahl R, Nyström PO, Almer S, Andersson P.
    Dis Colon Rectum; 2009 Aug 01; 52(8):1387-94. PubMed ID: 19617749
    [Abstract] [Full Text] [Related]

  • 16. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease.
    Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB, Bauer JJ.
    J Clin Gastroenterol; 2013 Jul 01; 47(6):491-5. PubMed ID: 23090048
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 20. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.